Source link : https://www.newshealth.biz/health-news/gene-therapy-for-hemophilia-b-significantly-outperforms-factor-ix-prophylaxis/
Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The annualized rate of bleeding for total bleeding episodes decreased by 71% after treatment with fidanacogene elaparvovec (Beqvez), while the mean annualized rate of bleeding for treated […]
Author : News Health
Publish date : 2024-09-25 21:03:13
Copyright for syndicated content belongs to the linked Source.
Categories